Cassava Sciences, Inc. (SAVA)
After hours:
| Previous Close | 20.50 |
| Open | 20.65 |
| Bid | 20.50 x 600 |
| Ask | 20.57 x 1200 |
| Day's Range | 20.35 - 21.21 |
| 52 Week Range | 12.32 - 32.10 |
| Volume | |
| Avg. Volume | 725,280 |
| Market Cap | 888.701M |
| Beta (5Y Monthly) | -0.40 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.32 |
| Earnings Date | Apr 29, 2024 - May 03, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Dec 13, 2012 |
| 1y Target Est | N/A |
GlobeNewswireRedemption Date Announced for Warrants
Monday, May 6, 2024 is Last and Final Day to Exercise Warrants.Once Redeemed, the Warrants Will Cease to Exist and Have No Value. AUSTIN, Texas, April 15, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (“Cassava Sciences” or the "Company") today announced that Monday, May 6, 2024 is the last and final day to exercise the warrants that were previously distributed to its shareholders on January 3, 2024 (the “Warrants”). Holders who exercise their Warrants will receive 1.5 shares of
- GlobeNewswire
Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials
An Independent Data and Safety Monitoring Board (DSMB) Recently Evaluated the Interim Patient Safety Database for Oral Simufilam in On-going Phase 3 Trials. The DSMB Recommended Both Phase 3 Trials Continue as Planned, Without Modification. Final Clinical Safety Data for Simufilam Are Expected at the Conclusion of the Phase 3 Program. AUSTIN, Texas, March 25, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today announced th
Simply Wall St.Bullish Cassava Sciences Insiders Loaded Up On US$3.12m Of Stock
Quite a few insiders have dramatically grown their holdings in Cassava Sciences, Inc. ( NASDAQ:SAVA ) over the past 12...
